Advances in Drug Delivery for Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 1014
Special Issue Editor
Interests: breast cancer; triple-negative breast cancer; drug delivery, immunotherapy; signal transduction; epigenetics; cell signaling; microbiota
Special Issue Information
Dear Colleagues,
We are excited to announce a call for submissions to a Special Issue of Cancers entitled "Advances in Drug Delivery for Cancer Therapy". Cancer continues to pose a significant global health challenge, and the development of effective treatment strategies is paramount for improving patient outcomes. Drug delivery plays a crucial role in optimizing the efficacy and safety of cancer therapies.
This Special Issue aims to showcase the latest advancements, innovations, and research breakthroughs in the field of drug delivery specifically targeted towards cancer treatment. We welcome the submission of original research articles, reviews, and other relevant contributions that explore various aspects of drug delivery systems, including targeted drug delivery, immunotherapy, combination therapies, and emerging technologies.
By exploring novel drug delivery approaches, we can enhance the precision, efficacy, and selectivity of cancer treatments while minimizing their side effects and improving patient compliance. We encourage researchers and experts in the field to share their findings, insights, and perspectives to advance our understanding and promote the development of innovative drug delivery strategies for cancer therapy.
All submitted manuscripts will undergo a rigorous peer-review process to ensure the highest scientific quality and impact. We invite you to contribute to this Special Issue and help shape the future of drug delivery in cancer treatment.
Dr. Ashakumary Lakshmikuttyamma
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- oncology
- therapeutic target
- drug resistance
- immunotherapy
- chemotherapy
- small molecule inhibitors
- drug delivery
- nanoparticle
